S&P 500   3,140.96 (+0.27%)
DOW   27,901.25 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.62 (+0.80%)
FB   202.48 (+0.80%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.08 (+0.09%)
NVDA   217.17 (+1.49%)
MU   49.23 (+3.73%)
BABA   204.24 (+1.89%)
T   38.18 (+0.29%)
PRI   135.51 (+0.18%)
NFLX   299.29 (+2.10%)
BAC   33.70 (+0.48%)
GILD   67.74 (+0.98%)
DIS   147.60 (+1.03%)
S&P 500   3,140.96 (+0.27%)
DOW   27,901.25 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.62 (+0.80%)
FB   202.48 (+0.80%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.08 (+0.09%)
NVDA   217.17 (+1.49%)
MU   49.23 (+3.73%)
BABA   204.24 (+1.89%)
T   38.18 (+0.29%)
PRI   135.51 (+0.18%)
NFLX   299.29 (+2.10%)
BAC   33.70 (+0.48%)
GILD   67.74 (+0.98%)
DIS   147.60 (+1.03%)
S&P 500   3,140.96 (+0.27%)
DOW   27,901.25 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.62 (+0.80%)
FB   202.48 (+0.80%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.08 (+0.09%)
NVDA   217.17 (+1.49%)
MU   49.23 (+3.73%)
BABA   204.24 (+1.89%)
T   38.18 (+0.29%)
PRI   135.51 (+0.18%)
NFLX   299.29 (+2.10%)
BAC   33.70 (+0.48%)
GILD   67.74 (+0.98%)
DIS   147.60 (+1.03%)
S&P 500   3,140.96 (+0.27%)
DOW   27,901.25 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.62 (+0.80%)
FB   202.48 (+0.80%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.08 (+0.09%)
NVDA   217.17 (+1.49%)
MU   49.23 (+3.73%)
BABA   204.24 (+1.89%)
T   38.18 (+0.29%)
PRI   135.51 (+0.18%)
NFLX   299.29 (+2.10%)
BAC   33.70 (+0.48%)
GILD   67.74 (+0.98%)
DIS   147.60 (+1.03%)
Log in

NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

$0.70
-0.02 (-2.78 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$0.70
Now: $0.70
$0.72
50-Day Range
$0.51
MA: $0.72
$0.94
52-Week Range
$0.47
Now: $0.70
$2.14
Volume25,439 shs
Average Volume3.99 million shs
Market Capitalization$112.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.41 million
Book Value($0.22) per share

Profitability

Net Income$-5,330,000.00

Miscellaneous

Employees17
Market Cap$112.52 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.


AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.10. The biopharmaceutical company earned $25.72 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 561.43% and a net margin of 120.85%. View AVEO Pharmaceuticals' Earnings History.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for AVEO Pharmaceuticals.

What price target have analysts set for AVEO?

6 equities research analysts have issued 1-year price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $1.00 to $3.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $2.15 in the next year. This suggests a possible upside of 207.1% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.

What is the consensus analysts' recommendation for AVEO Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)
  • 2. According to Zacks Investment Research, "AVEO missed on both earnings and revenues in the first quarter of 2019. The company got a huge boost from the approval for Fotivda in Europe regarding the first-line treatment of advanced renal cell carcinoma (RCC).However, AVEO faced a major setback when it had to delay its submission of a new drug application (NDA) for Fotivda in the United States. The company intended to submit the NDA in the first half of 2019 but now interim data will be available during the fourth quarter of 2019, subject to mature OS results. Although, the target market is lucrative, dependence on partners for pipeline development and funds accumulation is a concern. Failure to receive regulatory approvals or the termination of a deal would hamper AVEO’s future prospects. AVEO receives royalties from Fotivda sales in certain European countries. This is a key revenue driver. Shares of the company have underperformed the industry so far this year." (5/15/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

News headlines about AVEO stock have been trending neutral on Wednesday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 19,180,000 shares, an increase of 8.9% from the October 31st total of 17,610,000 shares. Based on an average daily volume of 2,390,000 shares, the days-to-cover ratio is presently 8.0 days. Currently, 14.3% of the shares of the stock are short sold. View AVEO Pharmaceuticals' Current Options Chain.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Micron Technology (MU), Opko Health (OPK), Alibaba Group (BABA), Novavax (NVAX), Amarin (AMRN), Bellicum Pharmaceuticals (BLCM) and Canopy Growth (CGC).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 59)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.35%) and Virtu Financial LLC (0.10%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for AVEO Pharmaceuticals.

Which major investors are buying AVEO Pharmaceuticals stock?

AVEO stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $0.70.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $112.52 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.View Additional Information About AVEO Pharmaceuticals.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  335 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel